Selected References:
- Citrome L. 2012. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract, 66(4):356-368.
- Dodd S, et al. 2011. A consensus statement for safety monitoring guidelines of treatments for major depressive disorder. Aust N Z J Psychiatry, 45(9):712-725.
- Morrison CM. 2014. A case report of the use of vilazodone in pregnancy. The primary care companion to CNS disorders, 16(2).
- Product Information: VIIBRYD(R) oral tablets, vilazodone HCl oral tablets. 2023. Allergan USA Inc (per FDA), Madison, NJ. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022567s022lbl.pdf
- Viibryd (vilazodone hydrochloride) Tablets Drug Approval Package. 2011. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000TOC.cfm
